Ceapro Reports Record Financial Results in First Quarter 2013
(firmenpresse) - EDMONTON, ALBERTA -- (Marketwired) -- 05/15/13 -- Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the Company") today announced record financial results for the first quarter ended March 31, 2013.
FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2013
"We are very pleased to report these financial results today which include record quarterly revenues and net income, well above 2012 levels. While these quarterly record sales and net income are marginally due to the rescheduled veterinary shampoo order from 2012, we expect better results in 2013 as we continue to focus on growth and cost management. The recent signing of a major three year distribution agreement with multinational Symrise will undoubtedly favour this positive trend, stated Gilles Gagnon, President and CEO of Ceapro. Having said this, breaking two million dollars in quarterly revenue is a milestone achievement in itself but getting it done while also advancing other transformational projects, makes this accomplishment even more impressive".
"From an investment perspective, our top priority remains the completion of our new manufacturing facility. We are on schedule to complete this monumental project by year end. This facility is essential for Ceapro's growth as it will allow the incorporation of new manufacturing technologies to ensure imroved margins, the introduction of new products for current and new markets, and the ability to consider contract manufacturing opportunities which have been presented to Ceapro. While our dedicated engineering team is working diligently on this project, our research and development team is advancing technologies on our value drivers, avenanthramides and beta glucan, especially for the development of new dry formulations with higher purity and concentation of active ingredients which should be suitable for the eventual transition to other large potential markets like functional food and drinks, nutraceuticals and/or pharmaceuticals" added Mr. Gagnon
FIRST QUARTER 2013 KEY OPERATIONAL HIGHLIGHTS
SUBSEQUENT TO FIRST QUARTER 2013
Announcement of a licensing and distribution agreement with multinational Symrise with a credit facility
The complete financial statements are available for review on SEDAR at and on the Company's website at .
About Ceapro Inc.
Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. To learn more about Ceapro, visit .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Branko Jankovic
Vice President and CFO
Ceapro Inc.
T (Edmonton): 780.917.8376
E:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.05.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 1227615
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
EDMONTON, ALBERTA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 113 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ceapro Reports Record Financial Results in First Quarter 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von
Ceapro Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
